We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
-4.22%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$16.9B
AUM Growth
-$2.13B
(-11%)
Cap. Flow
-$1.02B
Cap. Flow
% of AUM
-6.06%
Top 10 Holdings %
Top 10 Hldgs %
39.23%
Holding
1,372
New
74
Increased
459
Reduced
680
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$138M |
| 2 |
NVIDIA
NVDA
|
+$69.6M |
| 3 |
Synaptics
SYNA
|
+$37.7M |
| 4 |
Microchip Technology
MCHP
|
+$29.7M |
| 5 |
Lam Research
LRCX
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$184M |
| 2 |
iShares China Large-Cap ETF
FXI
|
+$170M |
| 3 |
XLNX
Xilinx Inc
XLNX
|
+$169M |
| 4 |
Apple
AAPL
|
+$131M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$110M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.16% |
| 2 | Financials | 15.03% |
| 3 | Energy | 6.15% |
| 4 | Healthcare | 5.33% |
| 5 | Consumer Discretionary | 2.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Alnylam Pharmaceuticals
ALNY
$29.5B
| $6.05M | 0.04% |
37,035
+5,090
| +16% | +$775K |
|
327
Twist Bioscience
TWST
$6.29B
| $6.03M | 0.04% |
122,098
+58,645
| +92% | +$3.25M |
|
328
Emergent Biosolutions
EBS
$382M
| $6.02M | 0.04% |
146,628
+14,963
| +11% | +$660K |
|
|
REGI
329
DELISTED
Renewable Energy Group, Inc.
REGI
| $6M | 0.04% |
98,930
-107,916
| -52% | -$5.23M |
|
330
Akamai
AKAM
$17.1B
| $6M | 0.04% |
50,224
-7,669
| -13% | -$860K |
|
|
BPMC
331
DELISTED
Blueprint Medicines
BPMC
| $5.98M | 0.04% |
93,635
+39,214
| +72% | +$2.81M |
|
332
Karyopharm Therapeutics
KPTI
$44.6M
| $5.96M | 0.04% |
53,929
+28,558
| +113% | +$3.56M |
|
|
EXAS
333
DELISTED
Exact Sciences
EXAS
| $5.96M | 0.04% |
85,214
+18,713
| +28% | +$1.37M |
|
334
PTC Therapeutics
PTCT
$5.68B
| $5.95M | 0.04% |
159,390
+17,237
| +12% | +$664K |
|
|
DVAX
335
DELISTED
Dynavax Technologies
DVAX
| $5.95M | 0.04% |
548,421
+152,838
| +39% | +$1.86M |
|
336
Ultragenyx Pharmaceutical
RARE
$2.46B
| $5.94M | 0.04% |
81,737
+14,046
| +21% | +$977K |
|
337
Everest Group
EG
$14.4B
| $5.89M | 0.03% |
19,559
-950
| -5% | -$273K |
|
338
JD.com
JD
$44.6B
| $5.87M | 0.03% |
101,501
+43,497
| +75% | +$2.96M |
|
339
FNB Corp
FNB
$6.83B
| $5.87M | 0.03% |
471,593
+29,459
| +7% | +$388K |
|
340
Baidu
BIDU
$38.3B
| $5.87M | 0.03% |
44,356
+15,356
| +53% | +$2.32M |
|
341
iShares MSCI Mexico ETF
EWW
$1.97B
| $5.85M | 0.03% |
106,492
-35,986
| -25% | -$1.81M |
|
342
Alkermes
ALKS
$8.31B
| $5.82M | 0.03% |
221,044
-23,079
| -9% | -$572K |
|
343
Ares Management
ARES
$31.3B
| $5.81M | 0.03% |
71,472
-3,455
| -5% | -$265K |
|
344
TG Therapeutics
TGTX
$7.07B
| $5.78M | 0.03% |
607,625
+289,391
| +91% | +$3.35M |
|
|
SAGE
345
DELISTED
Sage Therapeutics
SAGE
| $5.78M | 0.03% |
174,548
+35,792
| +26% | +$1.35M |
|
346
Exelixis
EXEL
$13.8B
| $5.78M | 0.03% |
254,747
-61,966
| -20% | -$1.21M |
|
347
Sarepta Therapeutics
SRPT
$1.68B
| $5.77M | 0.03% |
73,893
+7,782
| +12% | +$596K |
|
348
Ironwood Pharmaceuticals
IRWD
$728M
| $5.76M | 0.03% |
458,192
-18,594
| -4% | -$213K |
|
|
SRNE
349
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $5.76M | 0.03% |
2,470,682
+1,620,162
| +190% | +$5.05M |
|
350
Danaher
DHR
$139B
| $5.76M | 0.03% |
22,135
-2,194
| -9% | -$549K |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Rafferty Asset Management held 1,372 positions worth $16.9B, down 11% from $19B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Rafferty Asset Management withdrew a net $1.02B in Q1 2022, closing 155 positions and reducing 680 holdings. Its most notable exit was Xilinx Inc, an estimated $169M position sold in full.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Financials and Energy.
Against the trend, Rafferty Asset Management opened a new position in Synaptics worth $33.9M.
- Rafferty Asset Management's largest Q1 2022 buy was Synaptics: 170,061 shares worth $33.9M.
- Rafferty Asset Management added most to Advanced Micro Devices in Q1 2022, an estimated $138M increase.
- Rafferty Asset Management's biggest Q1 2022 reduction was iShares Russell 2000 ETF, cutting an estimated $184M.
- Rafferty Asset Management fully exited Xilinx Inc in Q1 2022, selling an estimated $169M.
- Rafferty Asset Management's ten largest holdings make up 39% of its $16.9B portfolio in Q1 2022.
- Rafferty Asset Management opened 74 new positions and closed 155 in Q1 2022.
- Rafferty Asset Management's portfolio value fell 11% quarter-over-quarter to $16.9B.
Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.